A Phase III Randomized Placebo-Controlled Study Evaluating Regorafenib Following Completion of Standard Chemotherapy for Patients with Stage III Colon Cancer (ARGO)
Protocol Chair: Carmen Allegra, MD
Protocol Officer: Samuel Jacobs, MD
Primary Objective: To determine whether treatment with regorafenib following adjuvant therapy improves disease-free survival (DFS) in patients with Stage IIIB or IIIC colon cancer
Patient Population: Surgically resected Stage III (IIIB or IIIC) colon cancer
Target Accrual: 1,118 patients
Status: Closed to accrual
ClinicalTrials.gov Identifier: NCT02334077
The Mission of NSABP Foundation, Inc. is to design and conduct practice changing cancer research, including clinical trials and laboratory studies in the medical, surgical and prevention settings in order to improve the survival outcome and quality of life of patients with breast and colorectal cancer, and to disseminate the results of NSABP collaborative research to benefit the world-wide community.
NSABP Foundation Inc.
Nova Tower 2
Two Allegheny Center – Suite 1200
Pittsburgh, PA 15212-5402